Former CDRH director joins Public Citizen in demanding recall of Stryker’s brain stent

Updated Dec. 22, 2011, at 12:30 p.m. to include comments from Stryker.

Brain stenting

Consumer watchdog group Public Citizen asked the federal government to recall Stryker Corp.’s (NYSE:SYK) Wingspan brain stent over concerns that it may lead to heightened risk of stroke and death.

Former FDA medical device director Larry Kessler joined the petition, asking that the agency pull the stents off the market and revoke their 510(k) clearance "because, when combined with aggressive medical treatment, they provide no additional benefit but cause significantly more harm than safer aggressive medical treatment alone," according to the petition.

The Wingspan system, cleared under the FDA’s humanitarian device exemption pathway in 2005, places a stent in narrowed arteries supplying blood to the brain.

Stryker is currently the only company with the FDA’s okay to sell a brain stent for certain high-risk patients in the U.S., having acquired it as part of a  $1.5 billion cash buyout of Boston Scientific Corp.’s (NYSE:BSX) neurovascular business in October of last year.

Among growing concern resulting from the National Institutes of Health SAMMPRIS study, the Kalamazoo, Mich.-based orthopedics giant defended the stent system, noting that the NIH study didn’t consider the device as it’s intended to be used.

"The SAMMPRIS trial did not follow the current HDE indication for use; it focused on studying the treatment of severe intracranial atherosclerotic disease, early in the treatment lifecycle and with an aggressive drug treatment regimen and rigorous oversight of medication compliance," Stryker spokeswoman Tamara Cutler told MassDevice in an email, adding that the system is cleared for use in no more than 4,000 patients per year.

"Stryker is committed to partnering with the NIH, FDA and study leaders to better understand and interpret the SAMMPRIS trial results," Cutler told us.

HDE standards for effectiveness are less stringent than pre-market approval submissions, and Boston Scientific won clearance with a single trial of 45 patients, Public Citizen wrote. The device is cleared for high-risk patients who have suffered one stroke and are likely to experience another.

"I can see no reason why this device should continue to be available," Kessler wrote in a letter in support of Public Citizen’s petition. "I understand that the FDA needs to use its regulatory authority in flexible and not dogmatic ways and granting of HDEs when data about safety and effectiveness are not complete is a legitimate exercise of regulatory authority. However, for that flexibility, the FDA must realize it has an equally important duty to move swiftly to make regulatory changes and announcements when device problems are uncovered."

Kessler spent more than 6 years as the director for the Office of Surveillance & Biometrics and another 6 years as director for the Office of Science & Engineering Laboratories at the Centers for Devices & Radiological Health at the FDA.

Public Citizen’s beef arises from recent research finding that patients treated with blood thinners and lifestyle coaching had lower rates of stroke and death than those who received the medication, guidance and the Wingspan brain stent.

"Stroke specialists are all disappointed that stenting did not have the beneficial impact we thought it would have," principal investigator at the University Hospital Case Medical Center arm Dr. Cathy Sila said in a press release in Sept. "The group that received aggressive medical therapy alone did far better than predicted with a 30 day stroke and death rate of only 5.8%. However, the group that received a stent as well as aggressive medical therapy did worse than predicted with a rate of 14.7%."

After one year, the stroke and death rate rose to 12.2% for the non-stented group and 20% for the patients who received the device, according to the study, which was sponsored by the National Institutes of Health and published in the New England Journal of Medicine.

"These compelling postmarket data about the Wingspan stent provide an opportunity for the FDA to show to industry, the clinical community, and most of all to patients that the Agency is serious about exercising its authority by withdrawing the HDE immediately and insisting on a recall to ensure the devices on the US market are both safe and effective.

Kessler was critical of the FDA for what he viewed as a lapse in action regarding recent studies warning of heightened risks of the Wingspan stents.

"I have looked at the FDA website and tried to find out whether the agency has even warned clinicians using a Medical Device Safety Communication," he wrote. "I cannot locate such a notice and would ask the FDA to explain why they have been so silent in the face of this significant trial showing clear concerns about this regulated medical device."

Public Citizen, a watchdog group founded by Ralph Nader, has also recently spoken out against transvaginal mesh products, asking the FDA to recall them after the agency released warnings that the device may expose patients to unnecessary risk without offering clinical benefit above safer options.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply